Alnylam Pharmaceuticals (ALNY)
(Real Time Quote from BATS)
$148.38 USD
+5.07 (3.54%)
Updated Apr 29, 2024 12:40 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALNY 148.38 +5.07(3.54%)
Will ALNY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ALNY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALNY
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?
ALNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Why Alnylam Pharmaceuticals (ALNY) Stock Might be a Great Pick
Should Invesco NASDAQ Next Gen 100 ETF (QQQJ) Be on Your Investing Radar?
Other News for ALNY
Alnylam Pharma: A Hold Rating Amidst Uncertainty Over Vutrisiran’s Clinical and Commercial Prospects
ProQR Therapeutics nominates Maier to board of directors
First Week of December 20th Options Trading For Alnylam Pharmaceuticals (ALNY)
How Is The Market Feeling About Alnylam Pharmaceuticals?
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results